1. Point-Substitution of Phenylalanine Residues of 26RFa Neuropeptide: A Structure-Activity Relationship Study
- Author
-
Olivier Le Marec, Nicolas Chartrel, Jean A. Boutin, Hubert Vaudry, Jérôme Leprince, Christophe Dubessy, Cindy Neveu, Karima Alim, Marie Christine Picot, David Vaudry, Julien Chuquet, Benjamin Lefranc, Gaëtan Prévost, Différenciation et communication neuronale et neuroendocrine (DC2N), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Plate-Forme de Recherche en Imagerie Cellulaire de Haute-Normandie (PRIMACEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches Internationales Servier [Suresnes] (IRIS), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), and Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Institut de Recherche pour le Développement (IRD)
- Subjects
Phenylalanine ,Pharmaceutical Science ,Neuropeptide ,Peptide ,CHO Cells ,[CHIM.THER]Chemical Sciences/Medicinal Chemistry ,QRFP ,Article ,Receptors, G-Protein-Coupled ,Analytical Chemistry ,Structure-Activity Relationship ,03 medical and health sciences ,Cricetulus ,QD241-441 ,0302 clinical medicine ,Drug Discovery ,Animals ,Humans ,GPR103 ,Structure–activity relationship ,Glucose homeostasis ,Physical and Theoretical Chemistry ,intracellular calcium concentration ,Receptor ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Peptide analog ,Neuropeptides ,Organic Chemistry ,RFamide ,Amino Acid Substitution ,chemistry ,Biochemistry ,Chemistry (miscellaneous) ,peptide analog ,Molecular Medicine ,030217 neurology & neurosurgery - Abstract
26RFa is a neuropeptide that activates the rhodopsin-like G protein-coupled receptor QRFPR/GPR103. This peptidergic system is involved in the regulation of a wide array of physiological processes including feeding behavior and glucose homeostasis. Herein, the pharmacological profile of a homogenous library of QRFPR-targeting peptide derivatives was investigated in vitro on human QRFPR-transfected cells with the aim to provide possible insights into the structural determinants of the Phe residues to govern receptor activation. Our work advocates to include in next generations of 26RFa(20–26)-based QRFPR agonists effective substitutions for each Phe unit, i.e., replacement of the Phe22 residue by a constrained 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid moiety, and substitution of both Phe24 and Phe26 by their para-chloro counterpart. Taken as a whole, this study emphasizes that optimized modifications in the C-terminal part of 26RFa are mandatory to design selective and potent peptide agonists for human QRFPR.
- Published
- 2021